Medical Condition News

RSS

Targeting brain cleaning gene could help treat or prevent Alzheimer's

A gene responsible for compacting trash inside the brain appears to be a key player in Alzheimer's disease, and doctors may be able to target it to better treat or help prevent the devastating condition, new UVA Health research suggests.

10 Nov 2026

Mayo Clinic research advances treatment options for genitourinary cancers

Cancers of the reproductive and urinary organs, known as genitourinary cancers, affect millions of people worldwide each year. Yousef Zakharia, M.D., a Mayo Clinic medical oncologist, leads clinical research aimed at improving treatment results for patients with kidney, bladder and prostate cancers.

10 Nov 2026

Awake deep brain stimulation helps personalize treatment for essential tremor

Awake deep brain stimulation (DBS) surgery can provide information beyond what imaging alone can capture, helping clinicians personalize electrode placement for patients with essential tremor, according to a Mayo Clinic study published in Operative Neurosurgery.

10 Nov 2026

Protein marker detects early Huntington's disease before brain damage

Before motor or cognitive impairments appear and before brain volume loss becomes evident, some individuals carrying the genetic mutation that causes Huntington's disease already show signs of neuronal injury.

10 Nov 2026

Subtle changes in deep sleep before Alzheimer's symptoms appear

The study identifies slow-wave sleep alterations as potential biomarkers for Alzheimer's, emphasizing their role in cognitive health and disease progression.

10 Nov 2026

Common blood pressure drugs may improve ulcerative colitis therapy

A class of blood pressure medications may improve a widely used treatment for ulcerative colitis, the most common type of inflammatory bowel disease, suggests a new study, led by Northwestern Medicine and Kiel University in Germany, of thousands of patients with the disease.

10 Nov 2026

Tobacco use independently linked to anorectal sensorimotor dysfunction and fecal incontinence

Tobacco use is independently associated with anorectal sensorimotor dysfunction and fecal incontinence, according to a recent study published ahead of print in The American Journal of Gastroenterology.

10 Nov 2026

A weight-loss drug eased knee arthritis pain in two major trials

Retatrutide effectively alleviates knee pain and enhances mobility in obese osteoarthritis patients, but long-term safety and joint health remain uncertain.

10 Nov 2026

Could a common diabetes drug help prevent long COVID?

Metformin use soon after COVID-19 infection is associated with a 53% reduction in long COVID or death risk, reinforcing previous clinical findings.

10 Nov 2026

New $46M grant allows the University of Oxford and Boston Children’s Hospital to lead Genetic Medicines Hub within ARIA ecosystem

The University of Oxford and Boston Children’s Hospital, with collaboration from The Jackson Laboratory and N=1 Collaborative, have been selected to establish a new Genetic Medicines Hub, one of six research hubs within the Aligning Research to Impact Autism (ARIA) ecosystem.

10 Nov 2026

Could Ozempic and Wegovy affect unborn babies?

They’re the blockbuster drugs transforming weight loss, helping millions of people to shed unwanted pounds.

10 Nov 2026

Qureight’s fibrosis imaging biomarker selected by Contineum Therapeutics as a secondary endpoint in Phase 2 PROPEL-IPF clinical trial

Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, and Contineum Therapeutics, Inc. (Contineum), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that Qureight’s Fibr8™ quantitative imaging biomarker is being used as a secondary endpoint in Contineum’s PROPEL-IPF Phase 2 clinical trial examining the safety and efficacy of PIPE-791, Contineum’s lead drug candidate, in idiopathic pulmonary fibrosis (IPF) patients.

10 Nov 2026

European commission approves label expansion of Pepaxti to third-line treatment

Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announced that the European Commission (EC) has formally approved the Type II variation application for Pepaxti (melflufen).

From Oncopeptides AB (publ) 10 Nov 2026

‘Fossil record’ in stored blood samples lets scientists trace leukemia back decades before diagnosis

Scientists have reconstructed how acute myeloid leukemia (AML) develops over the decades before diagnosis, showing that in two-thirds of cases the first cancer-driving mutation had been acquired before the age of 20—more than 50 years before diagnosis.

10 Nov 2026

A child's sex may change how early sugar intake relates to body fat

A longitudinal study of 130 mother-child pairs found that added sugar intake during pregnancy was more strongly associated with body fat in girls, whereas exposure during infancy was more strongly associated with adiposity in boys at age two. The findings, based largely on a smaller group of 42 children with usable body-composition scans, are preliminary and do not establish a causal relationship.

9 Nov 2026

DNA methylation patterns predict treatment response in MDS patients

DNA methylation patterns present at diagnosis could help predict which patients with myelodysplastic syndromes (MDS) will respond to azacitidine.

9 Nov 2026

UCLA study identifies lipid imbalance as pulmonary fibrosis trigger

A new UCLA Health study in mice has identified a new potential trigger for pulmonary fibrosis: lipid dysregulation (a fat imbalance) within alveolar macrophages.

9 Nov 2026

Australian-developed MND therapy advances to Phase 2 clinical trial

An Australian-developed therapy aimed at halting motor neurone disease progression and restoring function will advance to a national Phase 2 clinical trial.

9 Nov 2026

New treatment approach could help people with muscle-invasive bladder cancer live longer

A new treatment approach could help people with an aggressive form of bladder cancer live longer and reduce the chances of their cancer returning or progressing, particularly those who cannot receive standard chemotherapy, according to findings from a large international clinical trial co-led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center.

9 Nov 2026

Blocking complement factor B halts pancreatic cancer growth

Researchers have identified a promising new target in the treatment of pancreatic cancer. A new study in The American Journal of Pathology, published by Elsevier, demonstrates that blocking complement factor B (CFB), a pivotal enzyme in the alternative complement pathway, halts cancer growth and alters the tumor microenvironment.

9 Nov 2026